Disposition of 2533 shares by Christopher Starr of Monopar Therapeutics subject to Rule 16b-3

MNPR Stock  USD 22.98  0.76  3.42%   
Slightly above 55% of Monopar Therapeutics' retail investors are presently thinking to get in. The analysis of overall sentiment of trading Monopar Therapeutics stock suggests that some investors are interested at this time. Monopar Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Monopar Therapeutics. Many technical investors use Monopar Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Monopar Therapeutics Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Monopar insider trading alert for disposition of restricted stock units by Christopher Starr, Director, on 16th of December 2024. This event was filed by Monopar Therapeutics with SEC on 2023-03-31. Statement of changes in beneficial ownership - SEC Form 4

Monopar Therapeutics Fundamental Analysis

We analyze Monopar Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Valuation

Current Valuation Comparative Analysis

Monopar Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Monopar Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Monopar Therapeutics stock to make a market-neutral strategy. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics with similar companies.

Peers

Monopar Therapeutics Related Equities

ACRVAcrivon Therapeutics,   16.34   
0%
100.0%
KTTAPasithea Therapeutics   6.48   
0%
39.0%
ACXPAcurx Pharmaceuticals   5.95   
0%
36.0%
ANEBAnebulo Pharmaceuticals   4.43   
0%
27.0%
MLYSMineralys Therapeutics,   4.08   
0%
24.0%
CADLCandel Therapeutics   2.56   
0%
15.0%
MOLNMolecular Partners   2.53   
0%
15.0%
ANTXAN2 Therapeutics   2.16   
0%
13.0%
RZLTRezolute   1.75   
0%
10.0%
PEPGPepGen   1.59   
0%
9.0%
PMVPPmv Pharmaceuticals   1.31   
0%
8.0%
DMACDiaMedica Therapeutics   0.91   
0%
5.0%
SCPHScpharmaceuticals   0.56   
0%
3.0%
PHVSPharvaris   0.05   
1.0%
0%
AVTEAerovate Therapeutics   0.37   
2.0%
0%
ADAGAdagene   1.94   
11.0%
0%

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.